Amneal's IPX-203 shows promising results for motor fluctuations in Parkinson's disease

By Yahoo! Finance | Jun 17, 2024 at 01:53 AM EST

Amneal Pharmaceuticals' IPX-203, a combination of carbidopa and levodopa, successfully met primary and secondary endpoints in a Phase III trial for Parkinson's disease patients experiencing motor fluctuations. This oral gastric-retentive capsule offers a potential improvement over current treatments like Rytary.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.